Boston, MA 06/16/2014 (wallstreetpr) – Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is a bio-pharmaceutical company that mainly focuses on discovering, developing as well as commercializing drugs, and primarily targets G protein-coupled receptors. On June 13, 2014 the major pharmaceutical company announced that it is programmed to present a corporate overview on Wednesday, June 18, 2014.
2014 Wells Fargo Securities Healthcare Conference:
The official announcement was done on Friday, June 13, which explicitly stated that Arena will present a corporate overview at the ‘2014 Wells Fargo Securities Healthcare Conference’ at InterContinental Hotel in Boston, in Massachusetts. The conference is scheduled at around 2.25 p.m. A live audio webcast will be available on the company’s website, in the investor’s section for the customers and investors.
Phase 3 trials for BELVIQ presentation held at ADA:
On Monday, June 9, 2014 Arena and Eisai Inc acknowledged that the data of the Phase 3 clinical testing program for the BELVIQ (lorcaserin HCI) CIV will be demonstrated at the ADA’s (American Diabetes Association) 74th scientific session. The data is supposed to be presented by the company during the session from June 13, 2014 to June 17, 2014. The ADA session is taking place in San Francisco, California.
The Chief Clinical Officer of Eisai stated:
The Chief Clinical Officer and President of Neuroscience and General Medicine Product Creation Unit of Eisai, Lynn Kramer said that the company is committed towards advancing knowledge for the treatment of obesity, which is a chronic progressive disease having serious health consequences. The data presentation will support the company’s effort to promote greater understandings regarding obesity and lorcaserin.
BELVIQ is a U.S. approved serotonin 2C receptor used as an addition to a reduced calorie diet and boost physical activities for adults with BMI (Body Mass Index) of 30kg/ or more (obese) and 27kg/ or more (overweight). The oral presentation was conducted on June 14, 2014 at 9:00 a.m. followed by a poster presentation on the next day from 12: 00-2:00 p.m.
